SK pharmteco
SK pharmteco has been serving as a Global CDMO since January 2019, specializing in the commercial and clinical production of both small and large molecules. SK pharmteco offers a comprehensive range of services that includes process R&D, analytical method development, stability studies, scale-up and optimization, and the validation and commercial production of APIs, Advanced Intermediates, Registered Starting Materials, and Key Building Blocks. Additionally, SK pharmteco provides development, analytical services, and CGMP production for Cell Therapy, Viral Vectors, and Plasmids. Concurrently, SK biotek and SK biotek Ireland Limited have also engaged in contract development and manufacturing since November 2017, showcasing a strong commitment to the CDMO sector in the biopharmaceutical industry.
This person is not in any teams
SK pharmteco
Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group.